256 related articles for article (PubMed ID: 20722767)
1. Linguistic validation of the N-QOL (ICIQ), OAB-q (ICIQ), PPBC, OAB-S and ICIQ-MLUTSsex questionnaires in 16 languages.
McKown S; Abraham L; Coyne K; Gawlicki M; Piault E; Vats V
Int J Clin Pract; 2010 Nov; 64(12):1643-52. PubMed ID: 20722767
[TBL] [Abstract][Full Text] [Related]
2. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
3. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.
Coyne KS; Matza LS; Kopp Z; Abrams P
Eur Urol; 2006 Jun; 49(6):1079-86. PubMed ID: 16460875
[TBL] [Abstract][Full Text] [Related]
4. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
5. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
[TBL] [Abstract][Full Text] [Related]
6. Symptom severity and patient perceptions in overactive bladder: how are they related?
Homma Y; Gotoh M
BJU Int; 2009 Oct; 104(7):968-72. PubMed ID: 19338560
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
[TBL] [Abstract][Full Text] [Related]
8. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
[TBL] [Abstract][Full Text] [Related]
9. Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.
Zinner N; Kobashi K; Koochaki P; Fix D; Egermark M
Neurourol Urodyn; 2011 Jan; 30(1):62-8. PubMed ID: 20860020
[TBL] [Abstract][Full Text] [Related]
10. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
11. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
12. The psychometric validation of the OAB family impact measure (OAB-FIM).
Coyne KS; Matza LS; Brewster-Jordan J; Thompson C; Bavendam T
Neurourol Urodyn; 2010 Mar; 29(3):359-69. PubMed ID: 19274760
[TBL] [Abstract][Full Text] [Related]
13. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
14. Impact of stress urinary incontinence and overactive bladder on quality of life in Thai women attending the urogynecology clinic.
Wattanayingcharoenchai R; Manonai J; Vannatim N; Saritapirak S; Imsomboon C; Chittacharoen A
J Med Assoc Thai; 2007 Jan; 90(1):26-31. PubMed ID: 17621729
[TBL] [Abstract][Full Text] [Related]
15. Translating overactive bladder questionnaires in 14 languages.
Acquadro C; Kopp Z; Coyne KS; Corcos J; Tubaro A; Choo MS; Oh SJ
Urology; 2006 Mar; 67(3):536-40. PubMed ID: 16527574
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A
J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275
[TBL] [Abstract][Full Text] [Related]
17. The validation of the Dutch OAB-q SF: An overactive bladder symptom bother and health-related quality of life short-form questionnaire.
Groenendijk IM; Scheepe JR; Noordhoff TC; Blok BFM
Neurourol Urodyn; 2019 Aug; 38(6):1775-1782. PubMed ID: 31215693
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China.
Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X
Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714
[TBL] [Abstract][Full Text] [Related]
19. The validation of international consultation on incontinence questionnaires in the Greek language.
Athanasiou S; Grigoriadis T; Kyriakidou N; Giannoulis G; Antsaklis A
Neurourol Urodyn; 2012 Sep; 31(7):1141-4. PubMed ID: 22508384
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
